4znn - Revision history

OCA at 12:16, 6 March 2024

2024-03-06T12:16:15Z

←Older revision		Revision as of 12:16, 6 March 2024
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4znn]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ZNN OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4ZNN FirstGlance]. <br>		<table><tr><td colspan='2'>[[4znn]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ZNN OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4ZNN FirstGlance]. <br>
-	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4znn FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4znn OCA], [https://pdbe.org/4znn PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4znn RCSB], [https://www.ebi.ac.uk/pdbsum/4znn PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4znn ProSAT]</span></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">Electron crystallography, [[Resolution\|Resolution]] 1.41Å</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4znn FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4znn OCA], [https://pdbe.org/4znn PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4znn RCSB], [https://www.ebi.ac.uk/pdbsum/4znn PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4znn ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 10:		Line 11:
	== Function ==		== Function ==
	[https://www.uniprot.org/uniprot/SYUA_HUMAN SYUA_HUMAN] May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation.		[https://www.uniprot.org/uniprot/SYUA_HUMAN SYUA_HUMAN] May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation.
-	<div style="background-color:#fffaf0;">
-	== Publication Abstract from PubMed ==
-	The protein alpha-synuclein is the main component of Lewy bodies, the neuron-associated aggregates seen in Parkinson disease and other neurodegenerative pathologies. An 11-residue segment, which we term NACore, appears to be responsible for amyloid formation and cytotoxicity of human alpha-synuclein. Here we describe crystals of NACore that have dimensions smaller than the wavelength of visible light and thus are invisible by optical microscopy. As the crystals are thousands of times too small for structure determination by synchrotron X-ray diffraction, we use micro-electron diffraction to determine the structure at atomic resolution. The 1.4 A resolution structure demonstrates that this method can determine previously unknown protein structures and here yields, to our knowledge, the highest resolution achieved by any cryo-electron microscopy method to date. The structure exhibits protofibrils built of pairs of face-to-face beta-sheets. X-ray fibre diffraction patterns show the similarity of NACore to toxic fibrils of full-length alpha-synuclein. The NACore structure, together with that of a second segment, inspires a model for most of the ordered portion of the toxic, full-length alpha-synuclein fibril, presenting opportunities for the design of inhibitors of alpha-synuclein fibrils.
-
-	Structure of the toxic core of alpha-synuclein from invisible crystals.,Rodriguez JA, Ivanova MI, Sawaya MR, Cascio D, Reyes FE, Shi D, Sangwan S, Guenther EL, Johnson LM, Zhang M, Jiang L, Arbing MA, Nannenga BL, Hattne J, Whitelegge J, Brewster AS, Messerschmidt M, Boutet S, Sauter NK, Gonen T, Eisenberg DS Nature. 2015 Sep 24;525(7570):486-90. doi: 10.1038/nature15368. Epub 2015 Sep 9. PMID:26352473<ref>PMID:26352473</ref>
-
-	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	</div>
-	<div class="pdbe-citations 4znn" style="background-color:#fffaf0;"></div>

	==See Also==		==See Also==

OCA at 07:34, 18 May 2023

2023-05-18T07:34:48Z

←Older revision		Revision as of 07:34, 18 May 2023
Line 3:		Line 3:
	<StructureSection load='4znn' size='340' side='right'caption='[[4znn]], [[Resolution\|resolution]] 1.41Å' scene=''>		<StructureSection load='4znn' size='340' side='right'caption='[[4znn]], [[Resolution\|resolution]] 1.41Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4znn]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ZNN OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4ZNN FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4znn]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ZNN OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4ZNN FirstGlance]. <br>
-	</td></tr>~~<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4ril\|4ril]]</td></tr>~~	+	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4znn FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4znn OCA], [https://pdbe.org/4znn PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4znn RCSB], [https://www.ebi.ac.uk/pdbsum/4znn PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4znn ProSAT]</span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4znn FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4znn OCA], [~~http~~://pdbe.org/4znn PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=4znn RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/4znn PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=4znn ProSAT]</span></td></tr>	+
	</table>		</table>
	== Disease ==		== Disease ==
-	[~~[http~~://www.uniprot.org/uniprot/SYUA_HUMAN SYUA_HUMAN]] Note=Genetic alterations of SNCA resulting in aberrant polymerization into fibrils, are associated with several neurodegenerative diseases (synucleinopathies). SNCA fibrillar aggregates represent the major non A-beta component of Alzheimer disease amyloid plaque, and a major component of Lewy body inclusions. They are also found within Lewy body (LB)-like intraneuronal inclusions, glial inclusions and axonal spheroids in neurodegeneration with brain iron accumulation type 1. Defects in SNCA are the cause of Parkinson disease type 1 (PARK1) [MIM:[~~http~~://omim.org/entry/168601 168601]]. A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.<ref>PMID:9197268</ref> <ref>PMID:9462735</ref> <ref>PMID:14755719</ref> Defects in SNCA are the cause of Parkinson disease type 4 (PARK4) [MIM:[~~http~~://omim.org/entry/605543 605543]]. A complex neurodegenerative disorder with manifestations ranging from typical Parkinson disease to dementia with Lewy bodies. Clinical features include parkinsonian symptoms (tremor, rigidity, postural instability and bradykinesia), dementia, diffuse Lewy body pathology, autonomic dysfunction, hallucinations and paranoia. Defects in SNCA are the cause of dementia Lewy body (DLB) [MIM:[~~http~~://omim.org/entry/127750 127750]]. A neurodegenerative disorder clinically characterized by mental impairment leading to dementia, parkinsonism, often with fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Brainstem or cortical intraneuronal accumulations of aggregated proteins (Lewy bodies) are the only essential pathologic features. Patients may also have hippocampal and neocortical senile plaques, sometimes in sufficient number to fulfill the diagnostic criteria for Alzheimer disease.	+	[https://www.uniprot.org/uniprot/SYUA_HUMAN SYUA_HUMAN] Note=Genetic alterations of SNCA resulting in aberrant polymerization into fibrils, are associated with several neurodegenerative diseases (synucleinopathies). SNCA fibrillar aggregates represent the major non A-beta component of Alzheimer disease amyloid plaque, and a major component of Lewy body inclusions. They are also found within Lewy body (LB)-like intraneuronal inclusions, glial inclusions and axonal spheroids in neurodegeneration with brain iron accumulation type 1. Defects in SNCA are the cause of Parkinson disease type 1 (PARK1) [MIM:[https://omim.org/entry/168601 168601]. A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.<ref>PMID:9197268</ref> <ref>PMID:9462735</ref> <ref>PMID:14755719</ref> Defects in SNCA are the cause of Parkinson disease type 4 (PARK4) [MIM:[https://omim.org/entry/605543 605543]. A complex neurodegenerative disorder with manifestations ranging from typical Parkinson disease to dementia with Lewy bodies. Clinical features include parkinsonian symptoms (tremor, rigidity, postural instability and bradykinesia), dementia, diffuse Lewy body pathology, autonomic dysfunction, hallucinations and paranoia. Defects in SNCA are the cause of dementia Lewy body (DLB) [MIM:[https://omim.org/entry/127750 127750]. A neurodegenerative disorder clinically characterized by mental impairment leading to dementia, parkinsonism, often with fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Brainstem or cortical intraneuronal accumulations of aggregated proteins (Lewy bodies) are the only essential pathologic features. Patients may also have hippocampal and neocortical senile plaques, sometimes in sufficient number to fulfill the diagnostic criteria for Alzheimer disease.
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/SYUA_HUMAN SYUA_HUMAN]] May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation.	+	[https://www.uniprot.org/uniprot/SYUA_HUMAN SYUA_HUMAN] May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation.
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 20:		Line 19:
	</div>		</div>
	<div class="pdbe-citations 4znn" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 4znn" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Alpha-synuclein\|Alpha-synuclein]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Boutet, S]]	+	[[Category: Boutet S]]
-	[[Category: Brewster~~, A S~~]]	+	[[Category: Brewster AS]]
-	[[Category: Cascio, D]]	+	[[Category: Cascio D]]
-	[[Category: Eisenberg~~, D S~~]]	+	[[Category: Eisenberg DS]]
-	[[Category: Gonen, T]]	+	[[Category: Gonen T]]
-	[[Category: Guenther, E]]	+	[[Category: Guenther E]]
-	[[Category: Hattne, J]]	+	[[Category: Hattne J]]
-	[[Category: Ivanova, M]]	+	[[Category: Ivanova M]]
-	[[Category: Johnson, L]]	+	[[Category: Johnson L]]
-	[[Category: Messerschmidt, M]]	+	[[Category: Messerschmidt M]]
-	[[Category: Nannenga, B]]	+	[[Category: Nannenga B]]
-	[[Category: Reyes, F]]	+	[[Category: Reyes F]]
-	[[Category: Rodriguez~~, J A~~]]	+	[[Category: Rodriguez JA]]
-	[[Category: Sangwan, S]]	+	[[Category: Sangwan S]]
-	[[Category: Sauter~~, N K~~]]	+	[[Category: Sauter NK]]
-	[[Category: Sawaya~~, M R~~]]	+	[[Category: Sawaya MR]]
-	[[Category: Shi, D]]	+	[[Category: Shi D]]
-	~~[[Category: Alpha-synuclein]]~~	+
-	~~[[Category: Amyloid]]~~	+
-	~~[[Category: Lipid binding protein]]~~	+
-	~~[[Category: Nacore]]~~	+
-	~~[[Category: Parkinson's disease]]~~	+
-	~~[[Category: Toxic core~~]]	+

OCA at 08:44, 18 December 2019

2019-12-18T08:44:02Z

←Older revision		Revision as of 08:44, 18 December 2019
Line 1:		Line 1:

	==MicroED structure of the segment, GVVHGVTTVA, from the A53T familial mutant of Parkinson's disease protein, alpha-synuclein residues 47-56==		==MicroED structure of the segment, GVVHGVTTVA, from the A53T familial mutant of Parkinson's disease protein, alpha-synuclein residues 47-56==
-	<StructureSection load='4znn' size='340' side='right' caption='[[4znn]], [[Resolution\|resolution]] 1.41Å' scene=''>	+	<StructureSection load='4znn' size='340' side='right'caption='[[4znn]], [[Resolution\|resolution]] 1.41Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4znn]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ZNN OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ZNN FirstGlance]. <br>		<table><tr><td colspan='2'>[[4znn]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ZNN OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ZNN FirstGlance]. <br>
Line 24:		Line 24:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Large Structures]]
	[[Category: Boutet, S]]		[[Category: Boutet, S]]
	[[Category: Brewster, A S]]		[[Category: Brewster, A S]]

OCA at 18:42, 10 December 2016

2016-12-10T18:42:08Z

←Older revision		Revision as of 18:42, 10 December 2016
Line 1:		Line 1:
		+
	==MicroED structure of the segment, GVVHGVTTVA, from the A53T familial mutant of Parkinson's disease protein, alpha-synuclein residues 47-56==		==MicroED structure of the segment, GVVHGVTTVA, from the A53T familial mutant of Parkinson's disease protein, alpha-synuclein residues 47-56==
	<StructureSection load='4znn' size='340' side='right' caption='[[4znn]], [[Resolution\|resolution]] 1.41Å' scene=''>		<StructureSection load='4znn' size='340' side='right' caption='[[4znn]], [[Resolution\|resolution]] 1.41Å' scene=''>
Line 4:		Line 5:
	<table><tr><td colspan='2'>[[4znn]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ZNN OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ZNN FirstGlance]. <br>		<table><tr><td colspan='2'>[[4znn]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ZNN OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ZNN FirstGlance]. <br>
	</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4ril\|4ril]]</td></tr>		</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4ril\|4ril]]</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4znn FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4znn OCA], [http://pdbe.org/4znn PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4znn RCSB], [http://www.ebi.ac.uk/pdbsum/4znn PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4znn FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4znn OCA], [http://pdbe.org/4znn PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4znn RCSB], [http://www.ebi.ac.uk/pdbsum/4znn PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4znn ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==

OCA at 07:39, 30 September 2015

2015-09-30T07:39:50Z

←Older revision		Revision as of 07:39, 30 September 2015
Line 4:		Line 4:
	<table><tr><td colspan='2'>[[4znn]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ZNN OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ZNN FirstGlance]. <br>		<table><tr><td colspan='2'>[[4znn]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ZNN OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ZNN FirstGlance]. <br>
	</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4ril\|4ril]]</td></tr>		</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4ril\|4ril]]</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4znn FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4znn OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4znn RCSB], [http://www.ebi.ac.uk/pdbsum/4znn PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4znn FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4znn OCA], [http://pdbe.org/4znn PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4znn RCSB], [http://www.ebi.ac.uk/pdbsum/4znn PDBsum]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 10:		Line 10:
	== Function ==		== Function ==
	[[http://www.uniprot.org/uniprot/SYUA_HUMAN SYUA_HUMAN]] May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation.		[[http://www.uniprot.org/uniprot/SYUA_HUMAN SYUA_HUMAN]] May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation.
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	The protein alpha-synuclein is the main component of Lewy bodies, the neuron-associated aggregates seen in Parkinson disease and other neurodegenerative pathologies. An 11-residue segment, which we term NACore, appears to be responsible for amyloid formation and cytotoxicity of human alpha-synuclein. Here we describe crystals of NACore that have dimensions smaller than the wavelength of visible light and thus are invisible by optical microscopy. As the crystals are thousands of times too small for structure determination by synchrotron X-ray diffraction, we use micro-electron diffraction to determine the structure at atomic resolution. The 1.4 A resolution structure demonstrates that this method can determine previously unknown protein structures and here yields, to our knowledge, the highest resolution achieved by any cryo-electron microscopy method to date. The structure exhibits protofibrils built of pairs of face-to-face beta-sheets. X-ray fibre diffraction patterns show the similarity of NACore to toxic fibrils of full-length alpha-synuclein. The NACore structure, together with that of a second segment, inspires a model for most of the ordered portion of the toxic, full-length alpha-synuclein fibril, presenting opportunities for the design of inhibitors of alpha-synuclein fibrils.
		+
		+	Structure of the toxic core of alpha-synuclein from invisible crystals.,Rodriguez JA, Ivanova MI, Sawaya MR, Cascio D, Reyes FE, Shi D, Sangwan S, Guenther EL, Johnson LM, Zhang M, Jiang L, Arbing MA, Nannenga BL, Hattne J, Whitelegge J, Brewster AS, Messerschmidt M, Boutet S, Sauter NK, Gonen T, Eisenberg DS Nature. 2015 Sep 24;525(7570):486-90. doi: 10.1038/nature15368. Epub 2015 Sep 9. PMID:26352473<ref>PMID:26352473</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 4znn" style="background-color:#fffaf0;"></div>
	== References ==		== References ==
	<references/>		<references/>

OCA at 11:22, 9 September 2015

2015-09-09T11:22:04Z

←Older revision		Revision as of 11:22, 9 September 2015
Line 1:		Line 1:
-	'''~~Unreleased structure~~'''	+	==MicroED structure of the segment, GVVHGVTTVA, from the A53T familial mutant of Parkinson's disease protein, alpha-synuclein residues 47-56==
-		+	<StructureSection load='4znn' size='340' side='right' caption='[[4znn]], [[Resolution\|resolution]] 1.41Å' scene=''>
-	~~The entry~~ 4znn is ~~ON HOLD until Paper Publication~~	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[4znn]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ZNN OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ZNN FirstGlance]. <br>
-	~~Authors~~: ~~Rodriguez, J~~.A.~~, Ivanova, M~~., ~~Sawaya, M~~.R., ~~Cascio, D~~., ~~Reyes, F~~., ~~Shi, D~~., ~~Johnson~~, L., ~~Guenther~~, E., ~~Sangwan~~, S., ~~Hattne, J~~., ~~Nannenga, B~~., ~~Brewster, A~~.S., ~~Messerschmidt~~, M., ~~Boutet~~, S., ~~Sauter~~, N.K., ~~Gonen~~, T., ~~Eisenberg~~, D.S.	+	</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4ril\|4ril]]</td></tr>
-		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4znn FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4znn OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4znn RCSB], [http://www.ebi.ac.uk/pdbsum/4znn PDBsum]</span></td></tr>
-	~~Description: MicroED structure~~ of the ~~segment~~, ~~GVVHGVTTVA, from~~ the ~~A53T familial mutant of Parkinson's~~ disease ~~protein, alpha-synuclein residues 47-56~~	+	</table>
-	[[~~Category~~: ~~Unreleased Structures~~]]	+	== Disease ==
-	[[Category: ~~Johnson~~, L]]	+	[[http://www.uniprot.org/uniprot/SYUA_HUMAN SYUA_HUMAN]] Note=Genetic alterations of SNCA resulting in aberrant polymerization into fibrils, are associated with several neurodegenerative diseases (synucleinopathies). SNCA fibrillar aggregates represent the major non A-beta component of Alzheimer disease amyloid plaque, and a major component of Lewy body inclusions. They are also found within Lewy body (LB)-like intraneuronal inclusions, glial inclusions and axonal spheroids in neurodegeneration with brain iron accumulation type 1. Defects in SNCA are the cause of Parkinson disease type 1 (PARK1) [MIM:[http://omim.org/entry/168601 168601]]. A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.<ref>PMID:9197268</ref> <ref>PMID:9462735</ref> <ref>PMID:14755719</ref> Defects in SNCA are the cause of Parkinson disease type 4 (PARK4) [MIM:[http://omim.org/entry/605543 605543]]. A complex neurodegenerative disorder with manifestations ranging from typical Parkinson disease to dementia with Lewy bodies. Clinical features include parkinsonian symptoms (tremor, rigidity, postural instability and bradykinesia), dementia, diffuse Lewy body pathology, autonomic dysfunction, hallucinations and paranoia. Defects in SNCA are the cause of dementia Lewy body (DLB) [MIM:[http://omim.org/entry/127750 127750]]. A neurodegenerative disorder clinically characterized by mental impairment leading to dementia, parkinsonism, often with fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Brainstem or cortical intraneuronal accumulations of aggregated proteins (Lewy bodies) are the only essential pathologic features. Patients may also have hippocampal and neocortical senile plaques, sometimes in sufficient number to fulfill the diagnostic criteria for Alzheimer disease.
-	[[Category: ~~Sawaya~~, ~~M.R~~]]	+	== Function ==
-	[[Category: ~~Shi~~, D]]	+	[[http://www.uniprot.org/uniprot/SYUA_HUMAN SYUA_HUMAN]] May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation.
-	[[Category: ~~Reyes~~, F]]	+	== References ==
-	[[Category: ~~Eisenberg~~, ~~D.S~~]]	+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Boutet, S]]
		+	[[Category: Brewster, A S]]
		+	[[Category: Cascio, D]]
		+	[[Category: Eisenberg, D S]]
		+	[[Category: Gonen, T]]
	[[Category: Guenther, E]]		[[Category: Guenther, E]]
-	[[Category: Ivanova, M]]
	[[Category: Hattne, J]]		[[Category: Hattne, J]]
-	[[Category: ~~Nannenga~~, B]]	+	[[Category: Ivanova, M]]
-	[[Category: ~~Boutet~~, S]]	+	[[Category: Johnson, L]]
	[[Category: Messerschmidt, M]]		[[Category: Messerschmidt, M]]
-	[[Category: ~~Sauter~~, ~~N.K~~]]	+	[[Category: Nannenga, B]]
-	[[Category: ~~Gonen~~, ~~T]]~~	+	[[Category: Reyes, F]]
-	~~[[Category: Brewster, A.S~~]]	+	[[Category: Rodriguez, J A]]
-	[[Category: Rodriguez, J.A]]	+
-	~~[[Category: Cascio, D~~]]	+
	[[Category: Sangwan, S]]		[[Category: Sangwan, S]]
		+	[[Category: Sauter, N K]]
		+	[[Category: Sawaya, M R]]
		+	[[Category: Shi, D]]
		+	[[Category: Alpha-synuclein]]
		+	[[Category: Amyloid]]
		+	[[Category: Lipid binding protein]]
		+	[[Category: Nacore]]
		+	[[Category: Parkinson's disease]]
		+	[[Category: Toxic core]]

OCA at 10:55, 20 May 2015

2015-05-20T10:55:53Z

←Older revision		Revision as of 10:55, 20 May 2015
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 4znn is ON HOLD	+	The entry 4znn is ON HOLD until Paper Publication

	Authors: Rodriguez, J.A., Ivanova, M., Sawaya, M.R., Cascio, D., Reyes, F., Shi, D., Johnson, L., Guenther, E., Sangwan, S., Hattne, J., Nannenga, B., Brewster, A.S., Messerschmidt, M., Boutet, S., Sauter, N.K., Gonen, T., Eisenberg, D.S.		Authors: Rodriguez, J.A., Ivanova, M., Sawaya, M.R., Cascio, D., Reyes, F., Shi, D., Johnson, L., Guenther, E., Sangwan, S., Hattne, J., Nannenga, B., Brewster, A.S., Messerschmidt, M., Boutet, S., Sauter, N.K., Gonen, T., Eisenberg, D.S.

-	Description: ~~Electron Diffraction~~ structure of the segment, GVVHGVTTVA, from the A53T familial mutant of Parkinson's disease protein, alpha-synuclein residues, 47-56	+	Description: MicroED structure of the segment, GVVHGVTTVA, from the A53T familial mutant of Parkinson's disease protein, alpha-synuclein residues 47-56
	[[Category: Unreleased Structures]]		[[Category: Unreleased Structures]]
	[[Category: Johnson, L]]		[[Category: Johnson, L]]

OCA: Protected "4znn" [edit=sysop:move=sysop]

2015-05-13T11:10:30Z

Protected "4znn" [edit=sysop:move=sysop]

←Older revision

Revision as of 11:10, 13 May 2015

OCA: New page: '''Unreleased structure''' The entry 4znn is ON HOLD Authors: Rodriguez, J.A., Ivanova, M., Sawaya, M.R., Cascio, D., Reyes, F., Shi, D., Johnson, L., Guenther, E., Sangwan, S., Hattne,...

2015-05-13T11:10:29Z

New page: '''Unreleased structure''' The entry 4znn is ON HOLD Authors: Rodriguez, J.A., Ivanova, M., Sawaya, M.R., Cascio, D., Reyes, F., Shi, D., Johnson, L., Guenther, E., Sangwan, S., Hattne,...

New page

'''Unreleased structure'''

The entry 4znn is ON HOLD

Authors: Rodriguez, J.A., Ivanova, M., Sawaya, M.R., Cascio, D., Reyes, F., Shi, D., Johnson, L., Guenther, E., Sangwan, S., Hattne, J., Nannenga, B., Brewster, A.S., Messerschmidt, M., Boutet, S., Sauter, N.K., Gonen, T., Eisenberg, D.S.

Description: Electron Diffraction structure of the segment, GVVHGVTTVA, from the A53T familial mutant of Parkinson's disease protein, alpha-synuclein residues, 47-56
[[Category: Unreleased Structures]]
[[Category: Johnson, L]]
[[Category: Sawaya, M.R]]
[[Category: Shi, D]]
[[Category: Reyes, F]]
[[Category: Eisenberg, D.S]]
[[Category: Guenther, E]]
[[Category: Ivanova, M]]
[[Category: Hattne, J]]
[[Category: Nannenga, B]]
[[Category: Boutet, S]]
[[Category: Messerschmidt, M]]
[[Category: Sauter, N.K]]
[[Category: Gonen, T]]
[[Category: Brewster, A.S]]
[[Category: Rodriguez, J.A]]
[[Category: Cascio, D]]
[[Category: Sangwan, S]]